文献速递间质性肺疾病

特发性肺纤维化中抗修饰蛋白抗体的存在

Presence of anti-modified protein antibodies in idiopathic pulmonary fibrosis.
PubMed 文献 · Respirology · 2023-06-27

本研究纳入120例特发性肺纤维化(IPF)患者、120名性别和吸烟匹配的健康对照(HC)及104例类风湿关节炎(RA)患者,采用肽微阵列检测血清中针对天然及翻译后修饰肽的抗体。IPF患者中抗修饰蛋白抗体(AMPA)出现频率和水平高于HC(44% vs. 27%,p<0.01),但低于RA(44% vs. 79%,p<0.01)。IPF患者中AMPA存在与否与生存(p=0.13)或疾病进展(p=0.19)无差异,但新诊断IPF患者中AMPA存在者生存更好(p=0.009)。

要点

  • IPF患者血清AMPA阳性率44%,显著高于健康对照的27%。
  • IPF患者AMPA阳性率低于类风湿关节炎患者的79%。
  • 新诊断IPF患者中,AMPA存在与更好生存相关(p=0.009)。

核心结论

  • 相当比例IPF患者血清中存在特异性AMPA,提示自身免疫可能为影响疾病结局的IPF亚组特征。

研究设计与样本

  • 纳入120例新发和 prevalent IPF患者、120名性别和吸烟匹配的健康对照及104例RA患者。
  • 采用定制肽微阵列分析血清中针对天然及翻译后修饰(瓜氨酸化、乙酰化、氨甲酰化)肽的抗体,血清采集距诊断中位时间11个月(Q1-Q3:1-28个月)。

主要发现

  • IPF患者AMPA出现频率和水平高于HC(44% vs. 27%,p<0.01),但低于RA(44% vs. 79%,p<0.01)。
  • IPF患者中观察到针对特定瓜氨酸化、乙酰化和氨甲酰化肽的AMPA,包括tenascin、fibrinogen和filaggrin来源的肽段。
  • IPF患者中AMPA存在与否与生存(p=0.13)或疾病进展(p=0.19)无差异。
  • 新诊断IPF患者中,AMPA存在者生存更好(p=0.009)。

临床怎么用

  • IPF患者可检测血清AMPA,阳性结果可能提示自身免疫亚组,尤其在新诊断患者中或与更好生存相关。

以上解读依据论文摘要(全文未开放获取或许可不允许翻译转载)。

原文

BACKGROUND AND OBJECTIVE: Studies of autoimmunity and anti-citrullinated protein antibodies (ACPA) in idiopathic pulmonary fibrosis (IPF) have been confined to investigations of anti-cyclic citrullinated peptide (anti-CCP) antibodies which utilize synthetic peptides as surrogate markers for in vivo citrullinated antigens. We studied immune activation by analysing the prevalence of in vivo anti-modified protein antibodies (AMPA) in IPF. METHODS: We included patients with incident and prevalent IPF (N = 120), sex and smoking-matched healthy controls (HC) (N = 120) and patients with RA (N = 104). Serum (median time: 11 months [Q1-Q3: 1-28 months] from diagnosis) was analysed for presence of antibodies towards native and posttranslational modified (citrullinated [Cit, N = 25]; acetylated [Acet, N = 4] and homocitrullinated [Carb, N = 1]) peptides derived from tenascin (TNC, N = 9), fibrinogen (Fib, N = 11), filaggrin (Fil, N = 5), histone (N = 8), cathelicidin (LL37, N = 4) and vimentin (N = 5) using a custom-made peptide microarray. RESULTS: AMPA were more frequent and in increased levels in IPF than in HC (44% vs. 27%, p < 0.01), but less than in RA (44% vs. 79%, p < 0.01). We specifically observed AMPA in IPF towards certain citrullinated, acetylated and carbamylated peptides versus HC: tenascin (Cit(2033) -TNC2025-2040 ; Cit(2197) -TNC2177-2200 ; Cit(2198) -TNC2177-2200 ), fibrinogen (Cit(38,42) -Fibα36-50 ; Cit(72) -Fibβ60-74 ) and filaggrin (Acet-Fil307-324 , Carb-Fil307-324 ). No differences in survival (p = 0.13) or disease progression (p = 0.19) between individuals with or without AMPA was observed in IPF. However, patients with incident IPF had better survival if AMPA were present (p = 0.009). CONCLUSION: A significant proportion of IPF patients present with specific AMPA in serum. Our results suggest autoimmunity as a possible characteristic for a subgroup of IPF that may affect disease outcome.

来源:Respirology,查看原文。版权归原作者所有。

引用

  1. Kalafatis D, Joshua V, Hansson M, et al. Presence of anti-modified protein antibodies in idiopathic pulmonary fibrosis. Respirology. 2023. PMID: 37376768. doi:10.1111/resp.14543

供执业医师工作参考,不替代临床判断;数值与分级以指南原文为准。